Dear Editors
Studies antedating the advent of antipsychotics found an increased prevalence of abnormal glucose metabolism in patients with schizophrenia, although there were methodological limitations (Kohen, 2004) . Abnormal glucose tolerance has been observed in antipsychoticnaïve patients with first-episode psychosis (Fernandez-Egea et al., 2009) , as well as in the relatives of schizophrenia probands Spelman et al., 2007) . The concept of fetal origins of adult disease posits that events at key time points during gestation impact development and subsequent risk of adult disease (Schlotz et al., 2009) , and several risk factors (e.g., birth and maternal factors, and immune genes) are common to schizophrenia and type 2 diabetes (DM2) (Kandhal and Miller, 2013) . These findings suggest an increased risk of diabetes in schizophrenia, involving host-agent-environment interactions, that may be independent of antipsychotics. However, this intriguing hypothesis has been largely overshadowed by known metabolic side effects of second-generation antipsychotics (SGAs), which clearly increase the risk of DM2.
Several studies have reported an increased prevalence of a family history of DM2 in schizophrenia probands (Fernandez-Egea et al., 2008b; Mukherjee et al., 1989) . The present study investigates associations between parental DM2 and non-affective psychoses. We hypothesized that in probands with non-affective psychosis, there is an increased prevalence of parental DM2, which is also a predictor of comorbid diabetes.
Two-hundred seventeen inpatients and outpatients aged 18-70 diagnosed with schizophrenia (n=119), schizoaffective (n=88), psychosis NOS (n=9), or brief psychotic disorder (n=1), and 67 controls were recruited in Augusta, Georgia, between July 2010 and November 2015. Exclusion criteria have been reported elsewhere (Miller et al., 2015) . Medications were not standardized, although the majority (83%) were treated with SGA monotherapy. After written informed consent, subjects underwent a laboratory (blood draw between 8 and 9 AM after a ten-hour fast), physical and psychiatric diagnostic evaluation. Parental DM2 and psychiatric illness was obtained by self-report. Subjects were diagnosed with DM2 by either self-reported history or a fasting blood glucose ≥126 mg/dL. The study was approved by the IRB's of Augusta University and the Georgia Department of Community Health.
Demographic and clinical characteristics were analyzed using either a Chi-square test or Student's t-test (2-sided). Binary logistic regression models were used to evaluate subject group as a predictor of a parental DM2, controlling for age, sex, race, BMI, smoking, SES, and parental non-affective psychosis or bipolar disorder. Binary logistic regression models were also used to evaluate parental DM2 as a predictor of DM2 in non-affective psychosis, controlling for the same potential confounding factors. Results were considered statistically significant at the α=0.05 level (two-sided). The data were analyzed using SPSS, version 22.
The Table provides demographic information and regression analyses for the study sample. Data on parental DM2 were missing (unknown/not reported) for n=35 (16.1%) patients and n=6 (9.0%) controls. There was a significant increased prevalence of parental DM2 in nonaffective psychosis. Results were similar when restricting to subjects with schizophrenia, and subjects without a parental psychiatric history. After controlling for potential confounding factors, we found non-affective psychosis was associated with DM2 in the father (OR=3.7) or either parent (OR=2.8), consistent with previous studies (Fernandez-Egea et al., 2008b; Mukherjee et al., 1989) . There was also a significant increased prevalence of parental DM2 in subjects with non-affective psychosis and comorbid DM2. In regression, parental diabetes was a significant predictor of comorbid DM2 (OR=3.7) in nonaffective psychosis, also consistent with previous studies (Kusumi et al., 2011; Voruganti et al., 2007) . This association underscores that screening parental DM2 status is germane to the clinical care of patients with non-affective psychoses, as it may inform on risk of incident diabetes with antipsychotic treatment.
It is intriguing that in this convenience sample, we found significant associations between non-affective psychosis and parental DM2. We explored parent-of-origin effects, controlled for multiple potential confounding factors, and confirmed DM2 status by both medical history and laboratory testing. An important limitation was that parental DM2 was obtained by self-report only, inducing a potential selective recall bias. It might be expected that patients would be less likely than controls to remember parental history because of greater cognitive impairment; however, our subjects psychosis were more likely to report such a history. In controls, the prevalence of parental DM2 was similar to estimates in this region of Georgia (8.8-11.1%; Georgia Department of Public Health, 2012) . Our data do not allow us to determine whether the increased prevalence of parental DM2 is due to shared environmental or genetic factors, or gene-environment interactions. However, our results support the hypothesis that the development of DM2 in non-affective psychosis is multifactorial and not merely a result of SGA use. Miller et al. Page 4 
